Placed on Senate Legislative Calendar under General Orders. Calendar No. 43.
The bill adds a new Section 27 to the FTC Act prohibiting "product hopping," where branded drug manufacturers make changes that impede generic or biosimilar competition. It defines hard and soft switches, creates a prima facie framework for FTC enforcement after an ANDA or biosimilar application is filed, allows limited manufacturer justifications (safety, uncontrollable supply disruption, legitimate pro‑competitive reasons), and gives the FTC injunction, disgorgement, and restitution authority plus rulemaking power.
Libs emphasize patient savings and anti‑competitive fixes; conservatives emphasize investment and regulatory overreach.
Relative to its intended legislative type, this bill is a well-constructed statutory insertion that creates a substantive prohibition on product-hopping behavior with specific definitions, temporal limits, exceptions, justifications, enforcement mechanisms, and judicial-review processes.
The bill adds a new Section 27 to the FTC Act prohibiting "product hopping," where branded drug manufacturers make changes that impede generic or biosimilar competition.
It defines hard and soft switches, creates a prima facie framework for FTC enforcement after an ANDA or biosimilar application is filed, allows limited manufacturer justifications (safety, uncontrollable supply disruption, legitimate pro‑competitive reasons), and gives the FTC injunction, disgorgement, and restitution authority plus rulemaking power.
The provision applies to conduct and proceedings after enactment and preserves existing antitrust laws and judicial review paths.
Targeted, administrable reform with compromise elements improves prospects, but probable industry resistance and Senate procedural hurdles lower overall odds.
Relative to its intended legislative type, this bill is a well-constructed statutory insertion that creates a substantive prohibition on product-hopping behavior with specific definitions, temporal limits, exceptions, justifications, enforcement mechanisms, and judicial-review processes.
Libs emphasize patient savings and anti‑competitive fixes; conservatives emphasize investment and regulatory overreach.
These are examples from the analysis, not a ranked list of the most-affected groups.
Libs emphasize patient savings and anti‑competitive fixes; conservatives emphasize investment and regulatory overreach.
Likely broadly supportive: this creates a clear tool to stop tactics that delay lower‑cost generics and biosimilars.
It supports competition and potential patient cost savings while retaining safety and limited exceptions.
Cautiously favorable: the bill targets a specific anti‑competitive practice while keeping safety exceptions and judicial review.
Concerns focus on definitional clarity, predictable standards, and avoiding undue harm to legitimate innovation.
Likely skeptical or opposed: views this as an expansion of FTC power that interferes with manufacturers' product and inventory decisions, risks increased litigation, and could reduce incentives for pharmaceutical innovation.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Targeted, administrable reform with compromise elements improves prospects, but probable industry resistance and Senate procedural hurdles lower overall odds.
The bill has not accumulated any surfaced votes yet.
Libs emphasize patient savings and anti‑competitive fixes; conservatives emphasize investment and regulatory overreach.
Targeted, administrable reform with compromise elements improves prospects, but probable industry resistance and Senate procedural hurdles…
Relative to its intended legislative type, this bill is a well-constructed statutory insertion that creates a substantive prohibition on product-hopping behavior with specific definitions, temporal limits, exceptions, j…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.